axicabtagene ciloleucel + relmacabtagene autoleucel

**Axicabtagene ciloleucel + relmacabtagene autoleucel** is a combination of two autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapies used in relapsed/refractory large B-cell lymphoma. Axicabtagene ciloleucel (axi-cel), developed by Kite Pharma (Gilead), is a second-generation CAR-T with a CD28 co-stimulatory domain, while relmacabtagene autoleucel (relma-cel), developed by JW Therapeutics, uses a 4-1BB co-stimulatory domain and is approved exclusively in China. Patient T cells are collected, genetically modified ex vivo to express anti-CD19 CARs, expanded, and reinfused after lymphodepleting chemotherapy, enabling targeted killing of CD19-positive B-cell malignancies. Real-world data from Chinese patients show high response rates (ORR 86.7% at 3 months), with axi-cel achieving higher complete remission (100% vs 61.1%) but increased cytokine release syndrome severity compared to relma-cel.[1]

Other names

axi-cel + relma-cel